Background: Lamivudine resistance develops in up to 80% of patients with chronic hepatitis B (CHB) after 5 years of treatment. Cross-resistance between nucleoside/nucleotide analogues limits management options in these patients. To investigate the role of pegylated interferon-α2a as rescue therapy in these patients, the efficacy and safety of pegylated interferon-α2a between treatment-naive patients and lamivudine-resistant patients with hepatitis B e antigen (HBeAg)-positive CHB were compared.
Methods: A total of 150 HBeAg-positive CHB patients were stratified according to prior treatment. Lamivudine-resistant patients (n=64) and treatment-naive patients (n=86) received pegylated interferon-α2a once-weekly for 48 weeks and were followed-up for an additional 24 weeks. Primary end points were HBeAg loss and HBV DNA <100,000 copies/ml at end of follow-up.
Results: A total of 65 (76%) treatment-naive patients and 49 (77%) lamivudine-resistant patients completed treatment and 24 weeks of follow-up. Rates of HBeAg loss were comparable at end of follow-up between treatment-naive patients and lamivudine-resistant patients (20.9% and 23.4%, respectively; P=0.8423). Similarly, rates of HBV DNA<100,000 copies/ml were comparable at end of follow-up between treatment-naive patients and lamivudine-resistant patients (20.9% and 21.9%, respectively; P=1.000). There was no statistically significant difference in alanine aminotransferase normalization rates between treatment-naive patients and lamivudine-resistant patients (36.0% and 29.7%, respectively; P=0.4848). A total of one patient in each group achieved hepatitis B surface antigen (HBsAg) loss and seroconversion. The most common adverse events were those known to occur with pegylated interferon-α2a therapy, and safety profiles were similar between both patient populations.
Conclusions: Pegylated interferon-α2a may be effective as a rescue therapy in patients with lamivudine-resistant HBeAg-positive CHB.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.3851/IMP2664 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
PEGylated iron oxide-gold core-shell nanoparticles for tumor-targeted delivery of Rapamycin.
3 Biotech
January 2025
Department of Biotechnology, University of Calicut, Kerala Malappuram, 673635 India.
Rapamycin analogs are approved by the FDA for breast and renal cancer treatment. Hence, the possibility of nanoparticle-mediated delivery of Rapamycin could be examined. In the present study, PEGylated Gold-core shell iron oxide nanoparticles were used for the targeted delivery of Rapamycin, and R-Au-IONPs were formulated.
View Article and Find Full Text PDFSize-dependent Nanoparticle Accumulation In Venous Malformations.
J Vasc Anom (Phila)
December 2024
Laboratory for Biomaterials and Drug Delivery, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts.
Objective: The current treatment of venous malformations (VMs) consists of medications with systemic toxicity and procedural interventions with high technical difficulty and risk of hemorrhage. Using nanoparticles (NPs) to enhance drug delivery to VMs could enhance efficacy and decrease systemic toxicity. NPs can accumulate in tissues with abnormal vasculature, a concept known as the enhanced permeation and retention (EPR) effect.
View Article and Find Full Text PDFBacterial removal using liposomes and an anionic adsorber.
J Biosci Bioeng
December 2024
Division of Applied Life Sciences, Graduate School of Agriculture, Kyoto University, Sakyo-ku, Kyoto 606-8502, Japan.
Extracorporeal blood purification techniques using magnetic beads, which physically remove bacteria, fungi, viruses, and cytokines (disease agents) from the blood causing sepsis, have been studied. However, magnetic bead influx, which causes hemolysis and cytotoxicity, is an important issue. This study proposed a novel method for removing Escherichia coli from the blood using liposomes with high biocompatibility.
View Article and Find Full Text PDFEnhancing Ferroptosis-Mediated Radiosensitization Synergistic Disulfidptosis Induction.
ACS Nano
December 2024
Guangzhou Key Laboratory of Tumor Immunology Research, Cancer Research Institute, School of Basic Medical Sciences, Southern Medical University, Guangzhou 510515, P.R. China.
Ferroptosis plays an important role in radiotherapy (RT), and the induction of ferroptosis can effectively sensitize radiotherapy. However, the therapeutic efficiency is always affected by ferroptosis resistance, especially SLC7A11 (Solute Carrier Family 7 Member 11)-cystine-cysteine-GSH (glutathione)-GPX4 (glutathione peroxidase 4) pathway-mediated resistance. In this study, tumor-microenvironment self-activated high-Z element-containing nanoferroptosis inducers, PEGylated Fe-Bi-SS metal-organic frameworks (FBSP MOFs), were developed to sensitize RT.
View Article and Find Full Text PDFA multifunctional hyaluronic acid-engineered mesoporous nanoreactor with HO/O self-sufficiency for pH-triggered endo-lysosomal escape and synergetic cancer therapy.
Biomater Adv
December 2024
College of Materials Science and Engineering, Jilin Institute of Chemical Technology, Jilin City 132022, Jilin Province, PR China. Electronic address:
Monotherapy has poor accuracy and is easily restricted by tumor microenvironment (TME). Remodeling components of the TME to activate multimodal cancer therapy with high precision and efficiency is worth exploring. A multifunctional nanoreactor was fabricated by decorating chlorin e6-modified and PEGylated hyaluronic acid bearing diethylenetriamine-conjugated dihydrolipoic acid on the surface of glucose oxidase (GOx)-loaded hollow mesoporous CuS nanoparticles (labeled as GOx@HCuS@HA).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!